SI2812341T1 - C-terminalni inhibitorji HSP90 - Google Patents
C-terminalni inhibitorji HSP90Info
- Publication number
- SI2812341T1 SI2812341T1 SI201331622T SI201331622T SI2812341T1 SI 2812341 T1 SI2812341 T1 SI 2812341T1 SI 201331622 T SI201331622 T SI 201331622T SI 201331622 T SI201331622 T SI 201331622T SI 2812341 T1 SI2812341 T1 SI 2812341T1
- Authority
- SI
- Slovenia
- Prior art keywords
- hsp90 inhibitors
- terminal hsp90
- terminal
- inhibitors
- hsp90
- Prior art date
Links
- 210000004899 c-terminal region Anatomy 0.000 title 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/16—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings
- C07C211/17—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings containing only non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261597004P | 2012-02-09 | 2012-02-09 | |
| EP13706822.7A EP2812341B1 (en) | 2012-02-09 | 2013-02-08 | C-terminal hsp90 inhibitors |
| PCT/US2013/025387 WO2013119985A1 (en) | 2012-02-09 | 2013-02-08 | C-terminal hsp90 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2812341T1 true SI2812341T1 (sl) | 2020-02-28 |
Family
ID=47754998
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201331622T SI2812341T1 (sl) | 2012-02-09 | 2013-02-08 | C-terminalni inhibitorji HSP90 |
| SI201332079T SI3656758T1 (sl) | 2012-02-09 | 2013-02-08 | Intermediati za pripravo c-terminalnih inhibitorjev hsp90 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201332079T SI3656758T1 (sl) | 2012-02-09 | 2013-02-08 | Intermediati za pripravo c-terminalnih inhibitorjev hsp90 |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US9422320B2 (show.php) |
| EP (3) | EP3656758B1 (show.php) |
| JP (1) | JP6121450B2 (show.php) |
| KR (1) | KR102124109B1 (show.php) |
| CN (2) | CN107474085B (show.php) |
| AU (1) | AU2013216858C1 (show.php) |
| BR (1) | BR112014019704B1 (show.php) |
| CA (1) | CA2866814C (show.php) |
| CY (1) | CY1122358T1 (show.php) |
| DK (2) | DK2812341T3 (show.php) |
| EA (1) | EA027147B1 (show.php) |
| ES (2) | ES2755093T3 (show.php) |
| FI (1) | FI3656758T3 (show.php) |
| HR (2) | HRP20240514T1 (show.php) |
| HU (2) | HUE046939T2 (show.php) |
| LT (2) | LT3656758T (show.php) |
| MX (1) | MX361233B (show.php) |
| NZ (1) | NZ629778A (show.php) |
| PL (2) | PL2812341T3 (show.php) |
| PT (2) | PT2812341T (show.php) |
| RS (2) | RS59719B1 (show.php) |
| SI (2) | SI2812341T1 (show.php) |
| SM (2) | SMT201900660T1 (show.php) |
| WO (1) | WO2013119985A1 (show.php) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2866814C (en) | 2012-02-09 | 2021-02-16 | University Of Kansas | C-terminal hsp90 inhibitors |
| CA2951270C (en) | 2014-06-13 | 2023-07-04 | The University Of Kansas | Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors |
| SG11201610677XA (en) * | 2014-06-24 | 2017-01-27 | Univ Kansas | Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers |
| WO2016145219A1 (en) * | 2015-03-10 | 2016-09-15 | University Of Florida Research Foundation, Inc. | Treatment of peripheral neuropathies |
| EP3728275B1 (en) * | 2017-12-20 | 2024-09-04 | Merck Patent GmbH | Heteroaromatic compounds |
| PE20211446A1 (es) * | 2018-02-07 | 2021-08-05 | Reata Pharmaceuticals Inc | Formas de co-cristales de un analogo de novobiocina y prolina |
| US11827664B2 (en) * | 2018-05-14 | 2023-11-28 | Reata Pharmaceuticals, Inc | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9120774B2 (en) | 2004-11-03 | 2015-09-01 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| US8212012B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| US8212011B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues |
| US7608594B2 (en) | 2004-11-03 | 2009-10-27 | University Of Kansas | Novobiocin analogues as anticancer agents |
| US7622451B2 (en) | 2004-11-03 | 2009-11-24 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| WO2007095586A2 (en) * | 2006-02-14 | 2007-08-23 | The Trustees Of Columbia University In The City Of New York | Neuronal pain pathway modulators |
| GB0620259D0 (en) * | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| EP2131656A4 (en) | 2006-11-15 | 2011-12-07 | Forest Lab Holdings Ltd | phthalazine |
| EP2069324B1 (en) | 2007-03-20 | 2013-07-31 | Curis, Inc. | Fused amino pyridine as hsp90 inhibitors |
| US7960353B2 (en) * | 2007-05-10 | 2011-06-14 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| JP5766617B2 (ja) * | 2009-02-20 | 2015-08-19 | ユニバーシティ・オブ・カンザス | 修飾された糖部分を有するノボビオシン類似体 |
| US20110082098A1 (en) | 2009-09-30 | 2011-04-07 | University Of Kansas | Novobiocin analogues and treatment of polycystic kidney disease |
| TW201216957A (en) | 2010-07-13 | 2012-05-01 | Dainippon Sumitomo Pharma Co | Biarylamide derivative or a pharmaceutically acceptable salt thereof |
| CN101967125B (zh) * | 2010-10-08 | 2012-07-04 | 广州暨南生物医药研究开发基地有限公司 | 一种Hsp90抑制剂Xbj-B16-1及其制备方法与应用 |
| CN103596955B (zh) | 2011-04-05 | 2016-11-16 | 索隆-基特林癌症研究协会 | Hsp90抑制剂 |
| WO2012162054A1 (en) | 2011-05-20 | 2012-11-29 | The University Of Kansas | Dynamic inhibitors of heat shock protein 90 |
| CA2866814C (en) | 2012-02-09 | 2021-02-16 | University Of Kansas | C-terminal hsp90 inhibitors |
| AU2014346483B2 (en) | 2013-11-07 | 2019-01-17 | The University Of Kansas | Biphenylamide derivative Hsp90 inhibitors |
| WO2015070238A2 (en) | 2013-11-11 | 2015-05-14 | The University Of Kansas | Coumarin based hsp90 inhibitors with urea and ether substituents |
| CA2951270C (en) | 2014-06-13 | 2023-07-04 | The University Of Kansas | Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors |
| SG11201610677XA (en) | 2014-06-24 | 2017-01-27 | Univ Kansas | Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers |
| US11827664B2 (en) | 2018-05-14 | 2023-11-28 | Reata Pharmaceuticals, Inc | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway |
-
2013
- 2013-02-08 CA CA2866814A patent/CA2866814C/en active Active
- 2013-02-08 HR HRP20240514TT patent/HRP20240514T1/hr unknown
- 2013-02-08 EP EP19193576.6A patent/EP3656758B1/en active Active
- 2013-02-08 FI FIEP19193576.6T patent/FI3656758T3/fi active
- 2013-02-08 SI SI201331622T patent/SI2812341T1/sl unknown
- 2013-02-08 MX MX2014009608A patent/MX361233B/es active IP Right Grant
- 2013-02-08 SM SM20190660T patent/SMT201900660T1/it unknown
- 2013-02-08 BR BR112014019704-0A patent/BR112014019704B1/pt active IP Right Grant
- 2013-02-08 ES ES13706822T patent/ES2755093T3/es active Active
- 2013-02-08 DK DK13706822T patent/DK2812341T3/da active
- 2013-02-08 JP JP2014556739A patent/JP6121450B2/ja active Active
- 2013-02-08 PL PL13706822T patent/PL2812341T3/pl unknown
- 2013-02-08 PT PT137068227T patent/PT2812341T/pt unknown
- 2013-02-08 HU HUE13706822A patent/HUE046939T2/hu unknown
- 2013-02-08 AU AU2013216858A patent/AU2013216858C1/en active Active
- 2013-02-08 ES ES19193576T patent/ES2974721T3/es active Active
- 2013-02-08 RS RS20191454A patent/RS59719B1/sr unknown
- 2013-02-08 PT PT191935766T patent/PT3656758T/pt unknown
- 2013-02-08 EA EA201491496A patent/EA027147B1/ru unknown
- 2013-02-08 DK DK19193576.6T patent/DK3656758T3/da active
- 2013-02-08 HR HRP20191940TT patent/HRP20191940T1/hr unknown
- 2013-02-08 NZ NZ629778A patent/NZ629778A/en unknown
- 2013-02-08 US US14/377,616 patent/US9422320B2/en active Active
- 2013-02-08 WO PCT/US2013/025387 patent/WO2013119985A1/en not_active Ceased
- 2013-02-08 LT LTEP19193576.6T patent/LT3656758T/lt unknown
- 2013-02-08 PL PL19193576.6T patent/PL3656758T3/pl unknown
- 2013-02-08 KR KR1020147025348A patent/KR102124109B1/ko active Active
- 2013-02-08 HU HUE19193576A patent/HUE066259T2/hu unknown
- 2013-02-08 LT LT13706822T patent/LT2812341T/lt unknown
- 2013-02-08 CN CN201710729038.6A patent/CN107474085B/zh active Active
- 2013-02-08 SM SM20240145T patent/SMT202400145T1/it unknown
- 2013-02-08 SI SI201332079T patent/SI3656758T1/sl unknown
- 2013-02-08 EP EP13706822.7A patent/EP2812341B1/en active Active
- 2013-02-08 RS RS20240452A patent/RS65412B1/sr unknown
- 2013-02-08 EP EP24161059.1A patent/EP4403552A3/en active Pending
- 2013-02-08 CN CN201380019057.XA patent/CN104271587B/zh active Active
-
2016
- 2016-08-03 US US15/227,230 patent/US10030041B2/en active Active
-
2018
- 2018-06-26 US US16/018,401 patent/US10590157B2/en active Active
-
2019
- 2019-11-11 CY CY20191101180T patent/CY1122358T1/el unknown
-
2020
- 2020-02-05 US US16/783,025 patent/US10882881B2/en active Active
- 2020-12-04 US US17/112,060 patent/US11390640B2/en active Active
-
2022
- 2022-07-12 US US17/863,135 patent/US12024536B2/en active Active
-
2024
- 2024-05-17 US US18/667,496 patent/US20240417419A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT201900660T1 (it) | Inibitori c-terminali di hsp90 | |
| PL3434695T3 (pl) | Ulepszona immunoterapia | |
| EP2857033A4 (en) | PEPTIDE WITH SKIN PERMEATION | |
| GB201009732D0 (en) | Direct cloning | |
| ZA201406225B (en) | Thiadiazolidinediones as gsk-3 inhibitors | |
| GB201009853D0 (en) | HSP90 inhibitors | |
| IL235919A0 (en) | inhibitors of fbxo3 | |
| EP2885291A4 (en) | INHIBITORS OF VEGFR3 | |
| EP2885292A4 (en) | VEGFR3 INHIBITORS | |
| GB2504497B (en) | Armour | |
| ZA201503275B (en) | Transporter | |
| ZA201503127B (en) | Peptides | |
| GB201200555D0 (en) | Peptide | |
| GB201204868D0 (en) | Peptides | |
| GB201213560D0 (en) | Armour | |
| GB201223114D0 (en) | Novel peptide | |
| EP2891663A4 (en) | PEPTIDE DERIVED FROM PSF1 | |
| GB201220529D0 (en) | No details available | |
| GB201221414D0 (en) | Trans-locating peptide | |
| GB201200624D0 (en) | Peptide | |
| GB201200623D0 (en) | Peptide | |
| GB201220328D0 (en) | Peptides | |
| GB201211740D0 (en) | Peptides | |
| GB201207895D0 (en) | Peptides | |
| GB201200509D0 (en) | Peptides |